Guido Gerken

34.7k total citations · 4 hit papers
588 papers, 23.1k citations indexed

About

Guido Gerken is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Guido Gerken has authored 588 papers receiving a total of 23.1k indexed citations (citations by other indexed papers that have themselves been cited), including 345 papers in Hepatology, 290 papers in Epidemiology and 149 papers in Surgery. Recurrent topics in Guido Gerken's work include Liver Disease Diagnosis and Treatment (202 papers), Hepatitis C virus research (167 papers) and Hepatitis B Virus Studies (130 papers). Guido Gerken is often cited by papers focused on Liver Disease Diagnosis and Treatment (202 papers), Hepatitis C virus research (167 papers) and Hepatitis B Virus Studies (130 papers). Guido Gerken collaborates with scholars based in Germany, United States and United Kingdom. Guido Gerken's co-authors include Ali Canbay, Elke Cario, Daniel K. Podolsky, Percy A. Knolle, Lars P. Bechmann, JF Schlaak, Ulrich Treichel, Karl‐Hermann Meyer zum Büschenfelde, Ansgar W. Lohse and Michael P. Manns and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Guido Gerken

573 papers receiving 22.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

2005 866 citations Guido Gerken, Solko W. Schalm et al. profile →
The interaction of hepatic lipid and glucose metabolism in liver diseases

2011 762 citations Lars P. Bechmann, Guido Gerken et al. Journal of Hepatology profile →
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

2012 656 citations Antonio Craxı̀, Guido Gerken et al. Journal of Hepatology profile →
Toll-Like Receptor 2 Controls Mucosal Inflammation by Regulating Epithelial Barrier Function

2007 568 citations Guido Gerken et al. profile →

Peers

Countries citing papers authored by Guido Gerken

Since Specialization

Citations

This map shows the geographic impact of Guido Gerken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Gerken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Gerken more than expected).

Fields of papers citing papers by Guido Gerken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Gerken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Gerken. The network helps show where Guido Gerken may publish in the future.

Co-authorship network of co-authors of Guido Gerken

This figure shows the co-authorship network connecting the top 25 collaborators of Guido Gerken. A scholar is included among the top collaborators of Guido Gerken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guido Gerken. Guido Gerken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis 2023 ·Journal of Viral Hepatitis ·Ira M. Jacobson, Stefan Bourgeois, (unknown), Paul J. Thuluvath, Stephen Ryder, Guido Gerken, (unknown), Kim Vanstraelen, (unknown), Anu Osinusi, (unknown), Graham R. Foster	1
2	The predictive performance of SAPS 2 and SAPS 3 in an intermediate care unit for internal medicine at a German university transplant center; A retrospective analysis 2019 ·PLoS ONE ·Michael Jahn, Jan Rekowski, Guido Gerken, Andreas Kribben, Ali Canbay, Antonios Katsounas	15
3	The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype 2017 ·Transplant Infectious Disease ·(unknown), (unknown), Andreas Walker, Jörg Timm, Guido Gerken, Kerstin Herzer	3
4	Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently 2014 ·Gut ·A Beilfuss, Jan‐Peter Sowa, Svenja Sydor, Mechthild Beste, Lars P. Bechmann, Martin Schlattjan, Wing‐Kin Syn, Inga Wedemeyer, Zoltán Máthé, Christoph Jochum, Guido Gerken, Robert K. Gieseler, Ali Canbay	120
5	Orthotopic Liver Transplantation in Patients With Portal Vein Thrombosis in the Absence of Hepatocellular Carcinoma 2012 ·Transplantation Proceedings ·I. Fouzas, A. Paul, Christoph R. Becker, Spiridon Vernadakis, Jürgen Treckmann, Z. Máthé, Guido Gerken, G.C. Sotiropoulos	16
6	Apoptosis in selected liver diseases 2009 ·The Turkish Journal of Gastroenterology ·(unknown), Alişan Kahraman, Hikmet Akkız, (unknown), (unknown), Guido Gerken, Ali Canbay	9
7	Interferon-α Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells 2009 ·Journal of Interferon & Cytokine Research ·Vito R. Cicinnati, Jinyu Kang, (unknown), Monika Lindemann, (unknown), Thomas Tüting, Guido Gerken, Susanne Beckebaum	6
8	Major Histocompatibility Complex Class I–Related Chains A and B (Mic A/B): A Novel Role in Nonalcoholic Steatohepatitis 2009 ·Hepatology ·Alişan Kahraman, Martin Schlattjan, Peri Kocabayoglu, (unknown), Matthias Schlensak, Christian D. Fingas, Inga Wedemeyer, G. Marquitan, Robert K. Gieseler, Hideo A. Baba, Guido Gerken, Ali Canbay	102
9	581 HBV SUPPRESSES TLR-MEDIATED INNATE IMMUNE RESPONSES IN MURINE PARENCHYMAL AND NON-PARENCHYMAL LIVER CELLS 2008 ·Journal of Hepatology ·Jun Wu, Zhongji Meng, Martin Trippler, Ruth Broering, (unknown), (unknown), Ehydel Castro, (unknown), Ulf Dittmer, (unknown), Michael Roggendorf, Guido Gerken, Mengji Lu, JF Schlaak	2
10	Extent of liver resection modulates the activation of transcription factors and the production of cytokines involved in liver regeneration 2008 ·World Journal of Gastroenterology ·Jan‐Peter Sowa, Jan Best, Tamás Benkö, Maximillian Bockhorn, Yanli Gu, (unknown), (unknown), (unknown), Guido Gerken, Ursula Rauen, JF Schlaak	20
11	Das »Nußknacker-Syndrom« der Vena renalis (Arteria-mesenterica-superior-Syndrom) als Ursache gastrointestinaler Beschwerden 2008 ·DMW - Deutsche Medizinische Wochenschrift ·(unknown), K Oberholzer, K. H. Meyer zum Büschenfelde, R. Hohenfellner, Guido Gerken	4
12	Successful photodynamic therapy for biliary papillomatosis: A case report 2008 ·World Journal of Gastroenterology ·Lars P. Bechmann, Philip Hilgard, Andrea Frilling, Brigitte Schumacher, Hideo A. Baba, Guido Gerken, Thomas Zoepf	14
13	Utility of dark-lumen MR colonography for the assessment of extra-colonic organs 2007 ·European Radiology ·Waleed Ajaj, Stefan G. Ruehm, Susanne C. Ladd, Guido Gerken, Mathias Goyen	11
14	Effect of transient chemically induced colitis on the visceromotor response to mechanical colorectal distension 2002 ·European Journal of Gastroenterology & Hepatology ·Jürgen Gschossmann, Birgit Adam, Tobias Liebregts, (unknown), (unknown), Guido Gerken, Emeran A. Mayer, Gerald Holtmann	28
15	Lisofylline and Lysophospholipids Ameliorate Experimental Colitis in Rats 2002 ·Digestion ·Andreas Sturm, Jörg M. Zeeh, (unknown), Heiko C. Rath, Guido Gerken, Axel Dignaß	32
16	Local control of the immune response in the liver 2000 ·Immunological Reviews ·Percy A. Knolle, Guido Gerken	462
17	The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response 1999 ·Journal of Hepatology ·JF Schlaak, (unknown), H Löhr, Guido Gerken, (unknown)	27
18	The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials 1994 ·Journal of Hepatology ·Kim Krogsgaard, (unknown), Niels Bindslev, Erik Christensen, Antonio Craxı̀, P. Schlichting, Solko W. Schalm, Vicente Carréño, C. Trépo, Guido Gerken, Howard C. Thomas, Per Kragh Andersen, Helmer Ring‐Larsen	70
19	Chronic hepatitis delta virus (HDV) infection. 1991 ·PubMed ·Guido Gerken, K. H. Meyer zum Büschenfelde	3
20	Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies 1990 ·Journal of Hepatology ·B. De Wachter, Apostolos Kyriatsoulis, Ansgar W. Lohse, Guido Gerken, K.‐H. Meyer zum Büschenfelde, Michael Manns	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact